A scale of "bad" co-mutations in NPM1-driven AML

Abstract

In this issue of Blood, Dovey et al provide novel insights into the different ways in which the nucleophosmin (Npm1) mutation synergizes with its most common proliferative mutation partners (either Flt3ITD or NrasG12D/+) to give rise to acute myeloid leukemia (AML) with different features in genetically engineered mice.